Cargando…
Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study (‖)
Despite intensive treatment, 50% of children with high-risk neuroblastoma (HR-NB) succumb to their disease. Progression through current trials evaluating the efficacy of new treatments for children with HR disease usually depends on an inadequate response to induction chemotherapy, assessed using im...
Autores principales: | Morini, Martina, Cangelosi, Davide, Segalerba, Daniela, Marimpietri, Danilo, Raggi, Federica, Castellano, Aurora, Fruci, Doriana, Font de Mora, Jaime, Cañete, Adela, Yáñez, Yania, Viprey, Virginie, Corrias, Maria Valeria, Carlini, Barbara, Pezzolo, Annalisa, Schleiermacher, Gudrun, Mazzocco, Katia, Ladenstein, Ruth, Sementa, Angela Rita, Conte, Massimo, Garaventa, Alberto, Burchill, Susan, Luksch, Roberto, Bosco, Maria Carla, Eva, Alessandra, Varesio, Luigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826693/ https://www.ncbi.nlm.nih.gov/pubmed/31575060 http://dx.doi.org/10.3390/cancers11101476 |
Ejemplares similares
-
Immunohistochemical analysis of PDK1, PHD3 and HIF-1α expression defines the hypoxic status of neuroblastoma tumors
por: Ognibene, Marzia, et al.
Publicado: (2017) -
Suprarenal Masses in Very Young Infants: Is It Safe to Watch and Wait? Report of a SIOPEN Observational Study Results
por: Papadakis, Vassilios, et al.
Publicado: (2022) -
Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
por: Amoroso, Loredana, et al.
Publicado: (2018) -
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
por: Bellini, Angela, et al.
Publicado: (2021) -
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
por: Ladenstein, Ruth, et al.
Publicado: (2020)